CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $2.1B, above the global median of $1.15B
- FinancialsAltman Z-Score 12.28: safe zone
- Interpretations6 currently firing — 6
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
2.95%Above 5Y avg (2.41%)
Annual Rate
CNY 0.25Paid annual
Payout Ratio
35.7%Sustainable
Payback Period
35.9 yr
Last Ex-Dividend
May 29, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
14.13BCNY2.10B · vs all stocks (USD)
Trailing P/E
21.51xvs Biotechnology peers
Revenue (TTM)
2.56BCNY380.13M · vs all stocks (USD)
Profit Margin
27.11%vs Biotechnology peers
Beta
0.3560xvs all stocks
52-Week Change
-27.19%vs all stocks
Market Capitalization
14.13BCNY2.10B · vs all stocks (USD)
Enterprise Value
13.31BCNY1.98B · vs all stocks (USD)
Trailing P/E
21.51xvs Biotechnology peers
Forward P/E
12.42xvs Biotechnology peers
Price to Sales (TTM)
5.76xvs Biotechnology peers
Price to Book (MRQ)
3.12xvs Biotechnology peers
Enterprise to Revenue
5.20xvs Biotechnology peers
Enterprise to EBITDA
15.43xvs Biotechnology peers
Gross Margin
75.59%vs Biotechnology peers
Profit Margin
27.11%vs Biotechnology peers
Operating Margin
35.33%vs Biotechnology peers
Return on Assets (TTM)
8.67%vs Biotechnology peers
Return on Equity (TTM)
15.41%vs Biotechnology peers
Revenue (TTM)
2.56BCNY380.13M · vs all stocks (USD)
Revenue per Share (TTM)
1.55CNYUpdated Aug 19, 2026Quarterly Revenue Growth
-13.80%vs Biotechnology peers
Gross Profit (TTM)
1.91BCNY283.90M · vs all stocks (USD)
EBITDA (TTM)
833.36MCNY123.77M · vs all stocks (USD)
Net Income (TTM)
693.78MCNY103.04M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-19.80%vs Biotechnology peers
Operating Cash Flow (TTM)
808.82MCNY120.13M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
436.08MCNY64.77M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.2500CNYUpdated Aug 19, 2026Trailing Annual Dividend Yield
2.95%vs all stocks
5-Year Average Dividend Yield
2.41%vs all stocks
Payout Ratio
35.71%vs Biotechnology peers
Minority Interest (Equity)
178.34MCNYFY2025 · Dec 31, 2025Revenue
2.65BCNYFY2025 · Dec 31, 2025Cost of Goods Sold
643.16MCNYFY2025 · Dec 31, 2025Gross Profit
2.00BCNYFY2025 · Dec 31, 2025Operating Income
841.16MCNY124.93M · vs all stocks (USD)
Pre-tax Income
833.16MCNYFY2025 · Dec 31, 2025Income Tax Expense
85.82MCNYFY2025 · Dec 31, 2025Net Income
747.34MCNYFY2025 · Dec 31, 2025EBIT
835.09MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
978.89MCNYFY2025 · Dec 31, 2025Research & Development
219.45MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
617.09MCNYFY2025 · Dec 31, 2025Other Operating Expenses
22.58MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
3.48MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
1.93MCNYFY2025 · Dec 31, 2025EPS (Basic)
0.4400CNYFY2025 · Dec 31, 2025EPS (Diluted)
0.4400CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
1.67BSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
1.67BSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
747.34MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
-12.15MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
615.41MCNYFY2025 · Dec 31, 2025Free Cash Flow
506.12MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
238.20MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
747.34MCNYFY2025 · Dec 31, 2025Other Non-cash Items
4.30MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-129.40MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-6.82MCNYFY2025 · Dec 31, 2025Capital Expenditures
-109.30MCNYFY2025 · Dec 31, 2025Purchase of Investments
-1.52BCNYFY2025 · Dec 31, 2025Sale of Investments
1.17BCNYFY2025 · Dec 31, 2025Other Investing Activity
2.45MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-453.00MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
7.00MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-5.00MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-413.48MCNYFY2025 · Dec 31, 2025Other Financing Charges
-48.95MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-460.43MCNYFY2025 · Dec 31, 2025Shares Outstanding
1.67BSharesUpdated Aug 19, 2026Float Shares
1.05BSharesUpdated Aug 19, 2026% Held by Insiders
38.19%vs all stocks
% Held by Institutions
4.42%vs all stocks
Total Cash (MRQ)
1.66BCNY246.20M · vs all stocks (USD)
Total Cash per Share (MRQ)
0.9890CNYUpdated Aug 19, 2026Total Debt (MRQ)
30.24MCNY4.49M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0062xvs Biotechnology peers
Current Ratio (MRQ)
4.30xvs Biotechnology peers
Book Value per Share (MRQ)
2.83CNYUpdated Aug 19, 2026Total Assets
5.55BCNY823.94M · vs all stocks (USD)
Total Current Assets
2.40BCNYFY2025 · Dec 31, 2025Total Liabilities
811.30MCNYFY2025 · Dec 31, 2025Total Non-current Assets
3.15BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
171.60MCNYFY2025 · Dec 31, 2025Total Current Liabilities
639.70MCNYFY2025 · Dec 31, 2025Cash
209.84MCNYFY2025 · Dec 31, 2025Cash Equivalents
40.37MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
250.20MCNYFY2025 · Dec 31, 2025Other Short-term Investments
1.19BCNYFY2025 · Dec 31, 2025Accounts Receivable
407.94MCNYFY2025 · Dec 31, 2025Inventory
252.75MCNYFY2025 · Dec 31, 2025Accounts Payable
252.28MCNYFY2025 · Dec 31, 2025Short-term Debt
7.66MCNYFY2025 · Dec 31, 2025Other Current Liabilities
600.86KCNYFY2025 · Dec 31, 2025Long-term Debt
25.29MCNYFY2025 · Dec 31, 2025Other Non-current Liabilities
2.31MCNYFY2025 · Dec 31, 2025Common Stock (Book)
1.67BCNYFY2025 · Dec 31, 2025Retained Earnings
1.87BCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
4.74BCNY703.44M · vs all stocks (USD)
Treasury Stock
14.55MCNYFY2025 · Dec 31, 202552-Week Low
7.35CNYUpdated Aug 19, 202652-Week High
12.36CNYUpdated Aug 19, 202652-Week Change
-27.19%vs all stocks
Beta
0.3560xvs all stocks
50-Day MA
8.16CNYUpdated Aug 19, 2026200-Day MA
9.28CNYUpdated Aug 19, 2026Avg 10-Day Volume
33.02MSharesUpdated Aug 19, 2026Avg 30-Day Volume
27.28MSharesUpdated Aug 19, 2026Diluted EPS (TTM)
0.4100CNYUpdated Aug 19, 20266 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
MRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
Cash covers most of its debt, with earnings high against its liabilities.
Reads
How does this company use capital?
Cash-Flow Ratios Elevated
More of its sales turn into cash than in its industry, and less of that cash is consumed by reinvestment than at most of its peers.
Reads
Three Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion Levels
Its gross margin and its cash margin are high for its industry, and its operating margin is high outright.
Reads
Industry-Benchmarked ROA and Margin Elevated
Returns and margins have sat in the top of its industry across five years.
Reads
Three Margin Ratios Elevated Across Gross, Operating, And Net Levels
Its gross and net margins are high for its industry, and its operating margin is high outright.
Reads
ROE, ROA, And Operating ROA Elevated
It earns more on its equity than its industry does, and on its assets too — not on borrowing alone.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 12.28: safe zoneNotable
Altman Z-Score: 12.28
High structural barrier to entryNotable
Barrier to Entry: 0.66
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $2.1B, above the global median of $1.15BNotable
Market cap (USD): 2,099,200,688.926Global Median: 1,146,734,693.424
Levered free cash flow is $64.77M, above the global median of $16.24MNotable
Levered free cash flow (USD): 64,766,658.632Global Median: 16,239,329.704
Companies that share the same coordination system — how they create, deliver, or capture value.
GemPharmatech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineFlowRule
Verano Holdings Corp.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Hanall Biopharma Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Ab&B Bio-Tech Co., Ltd. (JS)
Tier 1ProductionApproval-Gated PipelineRule
Eris Lifesciences Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Axogen Inc.
Tier 1ProductionApproval-Gated PipelineRule
Kalbe Farma Tbk. PT
Tier 1ProductionApproval-Gated PipelineRuleFlow
Shandong Weigao Blood Purification Products Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Monte Rosa Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Mabwell (Shanghai) Bioscience Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
JCU Corp
6 interpretationsThree Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion LevelsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesROE, ROA, And Operating ROA ElevatedCash-Flow Ratios ElevatedIndustry-Benchmarked ROA and Margin ElevatedThree Margin Ratios Elevated Across Gross, Operating, And Net Levels
Sunplus Innovation Technology Inc.
6 interpretationsThree Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion LevelsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesROE, ROA, And Operating ROA ElevatedCash-Flow Ratios ElevatedIndustry-Benchmarked ROA and Margin ElevatedThree Margin Ratios Elevated Across Gross, Operating, And Net Levels
ASPEED Technology Inc.
6 interpretationsThree Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion LevelsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesROE, ROA, And Operating ROA ElevatedCash-Flow Ratios ElevatedIndustry-Benchmarked ROA and Margin ElevatedThree Margin Ratios Elevated Across Gross, Operating, And Net Levels